Drugs /

recombinant flt3 ligand

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine Flt3. Flt3 ligand binds to the Flt3 tyrosine kinase receptor and, synergistically with other growth factors, stimulates the proliferation and mobilization of bone marrow precursor cells, including CD34+ cells, and dendritic cells. When proteolytically cleaved, the transmembrane isoform of Flt3 ligand generates the soluble form soluble Flt3 ligand, which is also biologically active.

Clinical Trials

View Clinical Trials for recombinant flt3 ligand

Recombinant flt3 ligand has been investigated in 10 clinical trials, of which 10 are open and 0 are closed. Of the trials investigating recombinant flt3 ligand, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for recombinant flt3 ligand clinical trials.

Breast carcinoma, indolent non-hodgkin lymphoma, and non-small cell lung carcinoma are the most common diseases being investigated in recombinant flt3 ligand clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Recombinant Flt3 Ligand
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating recombinant flt3 ligand and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
flt3l, stk1-ligand, stem cell tyrosine kinase 1 ligand, flt 3 ligand, flt3-ligand, flk2 ligand, mobista, recombinant flt3 ligand, rhuflt3l, flt3 ligand, cdx-301, flt3 ligand protein, mobist, rflt3l, flk2-flt3 ligand, flt3 ligand, flt3l, fms-like tyrosine kinase 3 ligand, flt-3 ligand
Drug Target(s) [2]:
FLT3
NCIT ID [1]:
C1714

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.